JAHA:维生素K拮抗剂的摄入会增加心血管疾病风险

2018-08-29 MedSci MedSci原创

既往研究显示,维生素K拮抗剂(VKA)的使用与血管结构和功能的损伤相关,本研究的目的旨在评估VKA的摄入与不同类型心血管疾病发生的相关性。本研究纳入了15010名35岁至74岁的研究对象,包括287名VKA使用者和14564名非VKA使用者。多变量分析结果显示,VKA的摄入与硬化指数(β=+2.54 m/s; [0.41/4.66]; P=0.019)、踝肱指数(β=−0.03; [−0.04/−

既往研究显示,维生素K拮抗剂(VKA)的使用与血管结构和功能的损伤相关,本研究的目的旨在评估VKA的摄入与不同类型血管疾病发生的相关性。

本研究纳入了15010名35岁至74岁的研究对象,包括287名VKA使用者和14564名非VKA使用者。多变量分析结果显示,VKA的摄入与硬化指数(β=+2.54 m/s; [0.41/4.66]; P=0.019)、踝肱指数(β=−0.03; [−0.04/−0.01]; P<0.0001)、内膜-中层厚度(β=+0.03 mm [0.01/0.05]; P=0.0098)、左室射血分数(β=−4.02% [−4.70/−3.33]; P<0.0001)、左室质量(β=+5.34 g/m2.7 [4.26/6.44]; P<0.0001)和心功能与炎症的标志物呈相关性。另外,CYP2C9、CYP4F2和 VKORC1基因的遗传变异在VKA对心血管疾病发生中起到调节作用。

研究结果显示,维生素K拮抗剂与血管功能和心血管疾病不同亚型的发生相关。


原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1267904, encodeId=071a126e904e3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425715, encodeId=86051425e15d7, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436566, encodeId=ab1514365668e, content=<a href='/topic/show?id=6732e9086af' target=_blank style='color:#2F92EE;'>#维生素k拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79086, encryptionId=6732e9086af, topicName=维生素k拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473138, encodeId=bc3914e3138ac, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498466, encodeId=6ea214984664e, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511713, encodeId=de361511e136b, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=)]
    2018-08-31 zhaohui6731
  2. [GetPortalCommentsPageByObjectIdResponse(id=1267904, encodeId=071a126e904e3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425715, encodeId=86051425e15d7, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436566, encodeId=ab1514365668e, content=<a href='/topic/show?id=6732e9086af' target=_blank style='color:#2F92EE;'>#维生素k拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79086, encryptionId=6732e9086af, topicName=维生素k拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473138, encodeId=bc3914e3138ac, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498466, encodeId=6ea214984664e, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511713, encodeId=de361511e136b, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1267904, encodeId=071a126e904e3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425715, encodeId=86051425e15d7, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436566, encodeId=ab1514365668e, content=<a href='/topic/show?id=6732e9086af' target=_blank style='color:#2F92EE;'>#维生素k拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79086, encryptionId=6732e9086af, topicName=维生素k拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473138, encodeId=bc3914e3138ac, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498466, encodeId=6ea214984664e, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511713, encodeId=de361511e136b, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1267904, encodeId=071a126e904e3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425715, encodeId=86051425e15d7, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436566, encodeId=ab1514365668e, content=<a href='/topic/show?id=6732e9086af' target=_blank style='color:#2F92EE;'>#维生素k拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79086, encryptionId=6732e9086af, topicName=维生素k拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473138, encodeId=bc3914e3138ac, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498466, encodeId=6ea214984664e, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511713, encodeId=de361511e136b, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1267904, encodeId=071a126e904e3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425715, encodeId=86051425e15d7, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436566, encodeId=ab1514365668e, content=<a href='/topic/show?id=6732e9086af' target=_blank style='color:#2F92EE;'>#维生素k拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79086, encryptionId=6732e9086af, topicName=维生素k拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473138, encodeId=bc3914e3138ac, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498466, encodeId=6ea214984664e, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511713, encodeId=de361511e136b, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1267904, encodeId=071a126e904e3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425715, encodeId=86051425e15d7, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436566, encodeId=ab1514365668e, content=<a href='/topic/show?id=6732e9086af' target=_blank style='color:#2F92EE;'>#维生素k拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79086, encryptionId=6732e9086af, topicName=维生素k拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473138, encodeId=bc3914e3138ac, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498466, encodeId=6ea214984664e, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511713, encodeId=de361511e136b, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri Aug 31 04:18:00 CST 2018, time=2018-08-31, status=1, ipAttribution=)]

相关资讯

JACC:双重抗血小板治疗评分(DAPT)遭质疑

双重抗血小板治疗(DAPT)评分对冠脉支架植入术后的DAPT及同时存在的缺血和出血风险有指导意义。本研究的目的旨在通过全国范围内的人群评估DAPT评分的表现。本研究纳入了2006年至2014年瑞典国家数据库中的41101名冠脉支架植入后接受有12个月DAPT的患者,并根据DAPT评分对其心梗或支架血栓、主要不良心脑血管事件(MACCE)和大出血事件的风险进行了评估。分析结果显示,心梗或支架血栓的发

JACC:PEARS预防马凡综合征主动脉根部扩张安全有效

个性化的主动脉根部外支持(PEARS)是由2004年引进用来预防马凡综合征患者主动脉根部扩张的。本研究的目的旨在评估PEARS在预防马凡综合征患者主动脉根部扩张中的有效性。本研究纳入了24名马凡综合征患者,平均年龄为33 ± 13.3岁,主动脉根部平均直径为45 ± 2.8 mm,经过平均6.3 ± 2.6年时间的随访,患者主动脉根部和升主动脉直径没有增加,反而有减少的趋势,但是,降主动脉直径从2

JACC:肌钙蛋白I可预测COPD患者心血管疾病风险

慢性阻塞性肺疾病(COPD)患者发生心血管疾病的风险也会增高。本研究的目的旨在评估COPD患者肌钙蛋白I的水平与心血管疾病的相关性。本次随机双盲对照试验将16485名COPD伴心血管疾病或风险的患者随机分成安慰剂组、每天吸入糠酸氟替卡松组、维拉特罗组或两者均吸入的复合组。并对1599名患者的血浆高敏肌钙蛋白I水平进行检测。分析结果显示,有1542名(96%)患者的基础血浆高敏肌钙蛋白I水平超过了测

J Gernonto:肌肉力量弱的人更易早逝?

根据美国密歇根大学的一项新研究,肌肉力量弱的人通常不如强壮的人寿命长。

盘点:JACC8月第4期研究一览

1. 机械相关并发症在STEMI患者中的的变化趋势研究DOI: 10.1016/j.jacc.2018.06.031http://www.onlinejacc.org/content/72/9/959再灌注治疗大大降低了ST段抬高型心肌梗塞(STEMI)后的死亡率。本研究的目的旨在评估机械性相关并发症(MCs)随时间的发病率、管理和死亡率,以及其对老年STEMI患者短期死亡率的影响。本研究对1

JACC:肺功能的下降会增加心血管疾病风险

肺功能不全会增加心血管疾病(CVD)的发生风险。本研究的目的旨在评估肺功能的纵向下降是否与心衰、冠心病和卒中的发生相关。本研究纳入了ARIC 临床研究中的10351名无CVD的参与者,平均年龄为54 ± 6岁,女性占56%,白种人占81%。快速肺功能下降定义为1s用力呼气量(FEV1)或用力肺活量(FVC)下降的最大四分位数(n=2585)。经过平均17 ± 6年时间的随访,心衰的发生率为14%,